-
EP2932970
European procedure
Extract from the Register of European Patents
EP About this file: EP2932970
| EP2932970 - ANTIVIRAL THERAPY [Right-click to bookmark this link] | Status | Patent revoked Status updated on 14.02.2024 Database last updated on 14.03.2026 | |
| Former | The patent has been granted Status updated on 16.02.2018 | ||
| Former | Grant of patent is intended Status updated on 22.10.2017 | ||
| Former | Examination is in progress Status updated on 21.07.2017 | Most recent event Tooltip | 19.07.2024 | Lapse of the patent in a contracting state | published on 21.08.2024 [2024/34] | Applicant(s) | For all designated states VIIV Healthcare Company 251 Little Falls Drive Wilmington, DE 19808 / US | [2017/40] |
| Former [2016/20] | For all designated states VIIV Healthcare Company Corporation Service Company 2711 Centerville Road Suite 400 Wilmington DE 19808 / US | ||
| Former [2015/43] | For all designated states VIIV Healthcare Company CSC 2711 Centerville Road Suite 400 Wilmington, Delaware 19808 / US | Inventor(s) | 01 /
Underwood, Mark Richard c/o GlaxoSmithKline, Global Patents Dept Five Moore Drive Research Triangle Park, NC North Carolina 27709 / US | [2015/43] | Representative(s) | Gladwin, Amanda Rachel GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB | [2015/43] | Application number, filing date | 15164931.6 | 24.01.2011 | [2015/43] | Priority number, date | US20100298589P | 27.01.2010 Original published format: US 298589 P | [2015/43] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2932970 | Date: | 21.10.2015 | Language: | EN | [2015/43] | Type: | B1 Patent specification | No.: | EP2932970 | Date: | 21.03.2018 | Language: | EN | [2018/12] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 14.08.2015 | Classification | IPC: | A61K31/5365, A61K31/505, A61P31/18 | [2017/43] | CPC: |
A61K31/5365 (EP,EA,IL,KR,US);
A61K31/536 (IL,KR,US);
A61K31/505 (EP,EA,IL,US);
A61K31/4985 (EP,IL,KR,US);
A61K31/513 (EP,IL,KR,US);
A61K31/52 (IL,KR,US);
A61K31/675 (IL,US);
A61K45/06 (EP,IL,US);
A61K9/0014 (EP,IL,US);
A61K9/0019 (EP,IL,US);
A61K9/0053 (EP,IL,US);
A61P31/00 (EP,IL);
A61P31/12 (EP,IL);
A61P31/18 (EP,EA,IL);
A61P37/04 (EP,IL);
| C-Set: |
A61K31/4985, A61K2300/00 (EP);
A61K31/505, A61K2300/00 (EP);
A61K31/513, A61K2300/00 (EP,US);
A61K31/5365, A61K2300/00 (US,EP) |
| Former IPC [2015/43] | A61K31/4985, A61K31/52, A61K31/513, A61K31/536, A61P31/18 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/43] | Extension states | BA | 23.04.2015 | ME | 23.04.2015 | Title | German: | ANTIVIRALE THERAPIE | [2015/43] | English: | ANTIVIRAL THERAPY | [2015/43] | French: | THÉRAPIE ANTIVIRALE | [2015/43] | Examination procedure | 23.04.2015 | Examination requested [2015/43] | 15.04.2016 | Amendment by applicant (claims and/or description) | 20.07.2017 | Despatch of a communication from the examining division (Time limit: M02) | 05.09.2017 | Reply to a communication from the examining division | 23.10.2017 | Communication of intention to grant the patent | 05.02.2018 | Fee for grant paid | 05.02.2018 | Fee for publishing/printing paid | 05.02.2018 | Receipt of the translation of the claim(s) | 24.03.2022 | Observations by third parties | Parent application(s) Tooltip | EP11737484.3 / EP2531027 | Divisional application(s) | EP16187411.0 / EP3127542 | EP18161536.0 / EP3351249 | EP19151897.6 / EP3494972 | EP23214771.0 / EP4316599 | Opposition(s) | Opponent(s) | 01
19.12.2018
08.01.2019
ADMISSIBLE Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St. Tel Aviv 6944020 / IL Opponent's representative D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB | 02
21.12.2018
08.01.2019
ADMISSIBLE Cooke, Richard Elkington and Fife LLP Patents Department 3-4 Holborn Circus London EC1N 2HA / GB Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB | [N/P] |
| Former [2021/46] | |||
| Opponent(s) | 01
19.12.2018
08.01.2019
ADMISSIBLE Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St. Tel Aviv 6944020 / IL Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB | ||
| 02
21.12.2018
08.01.2019
ADMISSIBLE Cooke, Richard Elkington and Fife LLP Patents Department 3-4 Holborn Circus London EC1N 2HA / GB Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB | |||
| Former [2019/06] | |||
| Opponent(s) | 01
19.12.2018
ADMISSIBLE Teva Pharmaceutical Industries Ltd 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB | ||
| 02
21.12.2018
ADMISSIBLE Cooke, Richard Elkington and Fife LLP Patents Department 3-4 Holborn Circus London EC1N 2HA / GB Opponent's representative Elkington & Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB | |||
| Former [2019/04] | |||
| Opponent(s) | 01
19.12.2018
Teva Pharmaceutical Industries Ltd 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB | deleted | Deletion: Legal effect of rejection of opposition [ N /P ] | 15.01.2019 | Invitation to proprietor to file observations on the notice of opposition | 21.05.2019 | Reply of patent proprietor to notice(s) of opposition | 20.03.2020 | Cancellation of oral proceeding that was planned for 02.04.2020 | 02.04.2020 | Date of oral proceedings | 22.10.2020 | Cancellation of oral proceeding that was planned for 01.12.2020 | 01.12.2020 | Date of oral proceedings | 20.10.2021 | Date of despatch of rejection of opposition | 18.12.2023 | Legal effect of revocation of patent [2024/12] | 09.02.2024 | Despatch of communication that the patent will be revoked | Appeal following opposition | 06.12.2021 | Appeal received No. T2156/21 | 06.12.2021 | Payment of appeal fee | 24.02.2022 | Statement of grounds filed | 18.12.2023 | Result of appeal procedure: revocation of the patent | 09.02.2024 | Despatch of the decision of the Board of Appeal | 17.12.2021 | Appeal received No. T2156/21 | 17.12.2021 | Payment of appeal fee | 15.02.2022 | Statement of grounds filed | 18.12.2023 | Result of appeal procedure: revocation of the patent | 09.02.2024 | Despatch of the decision of the Board of Appeal | 18.12.2023 | Date of oral proceedings | Fees paid | Renewal fee | 23.04.2015 | Renewal fee patent year 03 | 23.04.2015 | Renewal fee patent year 04 | 23.04.2015 | Renewal fee patent year 05 | 08.01.2016 | Renewal fee patent year 06 | 09.01.2017 | Renewal fee patent year 07 | 08.01.2018 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | RS | 24.01.2011 | [2024/34] | Documents cited: | Search | [X] WO2009148600 (CONCERT PHARMACEUTICALS INC et al.) | [Y] WO2009007441 (TIBOTEC PHARM LTD et al.) | [YP] WO2010068253 (SHIONOGI & CO et al.) | [AP] WO2010011812 (SMITHKLINE BEECHAM CORP et al.) | [A] US2009318421 (JOHNS BRIAN ALVIN et al.) | [X] SONG I ET AL: "The Effect of Ritonavir-Boosted Protease Inhibitors on the HIV Integrase Inhibitor, S/GSK1349572, in Healthy Subjects", INTERNET CITATION, 12 September 2009 (2009-09-12), XP002697436, Retrieved from the Internet | [Y] "A Phase IIb Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance", 15 January 2010 (2010-01-15), XP002743041, Retrieved from the Internet | by applicant | WO2006116764 | WO2010068253 | WO2010068262 | US5034394 | US5089500 | US6294540 | US5641889 | US5840990 | US5919941 | US5808147 | US6392085 | US6448403 | US5917041 | US6087501 | US5917042 | US6555687 | US6552193 | US6870053 | US6340587 | US6646125 | US5047407 | US7119202 | US5905082 | US5696254 | US5663320 | US5693787 | US6051709 | US6329522 | US5922695 | US5935946 | US5977089 | US6043230 | US6069249 | US5519021 | US5663169 | US5811423 | US6555133 | US6639071 | US6939964 | US7534809 | US7109228 | US5914332 | US6436989 | US6514953 | US6281367 | US5849911 | US6087383 | PHARMACEUTICAL RESEARCH, vol. 3, no. 6, 1986, pages 318 | SELLESETH, D.W. ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 47, 2003, pages 1468 - 71 | Opposition | WO2009007441 | WO2011094150 | US298589 | WO03016306 | WO2005021001 | WO2006024668 | WO2006116764 | WO2009007441 | WO2011094150 | US29858910 | WO2006024024 | WO0154625 | EP1874117 | AZIJN ET AL.: "TMC278, a Next-Generation Nonnucleoside Reverse TranscriptaseInhibitor (NNRTI), Active against Wild-Type andNNRTI-Resistant HIV-lvt", ANTIMICROB AGENTS CHEMOTHER, vol. 54, no. 2, 23 November 2009 (2009-11-23), pages 718 - 727, XP055539824 DOI: http://dx.doi.org/10.1128/AAC.00986-09 | LALEEZARI ET AL.: "Potent Antiviral Activity of S/GSK1349572, A Next Generation integrase Inhibitor (INI), in INI-Nave HIV-1 -infected Patients: ING111521 Protocol", IAS 2009 - 5TH CONFERENCE ON HIV PATHOGENESIS, 19 July 2009 (2009-07-19), Cape Town South Africa, XP055280561 | ANONYMOUS: "Antiviral Activity of S/GSK1349572, the Only Once-Daily, UnboostedIntegrase Inhibitor In Clinical Development, Evaluated In Phase 2Study", GSK PRESS RELEASE, July 2009 (2009-07-01), XP055544606, Retrieved from the Internet | UNDERWOOD ET AL.: "S/SK1349572: A Next Generation Integrase Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical Isolates from Patients Experiencing Virologic Failure while on Raltegravir Therapy", IAS 2009 - 5TH CONFERENCE ON HIV PATHOGENESIS, 19 July 2009 (2009-07-19), XP055544612, Retrieved from the Internet | ROCKSTROH K.J. ET AL.: "Integrase inhibitors: Why do we need a new drug class for HIV therapy?", EUR J MED RES, vol. 14, no. Sup. III, 24 November 2009 (2009-11-24), pages 1 - 3, XP021130215 DOI: http://dx.doi.org/10.1186/2047-783X-14-S3-1 | JOHNS ET AL.: "The Discovery of S/GSK1349572: A Once Daily Next-Generation Integrase Inhibitor with a Superior Resistance Profile", 17TH CROI, CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, 16 February 2010 (2010-02-16), San Francisco CA, XP055539843 | POZNIAK ET AL.: "Efficacy and safety of TMC278 in antiretroviral-naive HIV- 1 patients: week 96 results of a phase IIb randomized trial", AIDS, vol. 24, no. 1, 2 January 2010 (2010-01-02), pages 55 - 66, XP055539845 DOI: http://dx.doi.org/10.1097/QAD.0b013e32833032ed | SCOTT M HAMMER ET AL: "Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society", JAMA, vol. 300, no. 5, 6 August 2008 (2008-08-06), pages 555 - 570, XP008134902 DOI: http://dx.doi.org/10.1001/jama.300.5.555 | "Guidelines for the use of ARVs Agents in adults and adolescents living with HIV", AIDS INFO, Retrieved from the Internet | GOEBEL FRANK ET AL: "Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1 infected subjects", AIDS, vol. 20, no. 13, 22 August 2006 (2006-08-22), pages 1721 - 1726, XP009087366 DOI: http://dx.doi.org/10.1097/01.aids.0000242818.65215.bd | VAN ROEY J. ET AL: "How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals", DRUG DISCOV TODAY, vol. 13, no. 13-14, 17 June 2008 (2008-06-17), pages 13 - 14, XP022797177 DOI: http://dx.doi.org/10.1016/j.drudis.2008.04.009 | AZIJN ET AL.: "TMC278, a Next-Generation Nonnucleoside Reverse TranscriptaseInhibitor (NNRTI), Active against Wild-Type andNNRTI-Resistant HIV-lvt", ANTIMICROB AGENTS CHEMOTHER, vol. 54, no. 2, 23 November 2009 (2009-11-23), pages 718 - 727, XP 055539824 DOI: http://dx.doi.org/10.1128/AAC.00986-09 | LALEEZARI ET AL.: "Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Naive HIV-1-Infected Patients: ING111521 Protocol", IAS 2009 - 5TH CONFERENCE ON HIV PATHOGENESIS, TREATMENT AND PREVENTION, 19 July 2009 (2009-07-19), Cape Town South Africa, XP 055280561 | ANONYMOUS: "Antiviral Activity of S/GSK1349572, the Only Once-Daily, Unboosted Integrase Inhibitor In Clinical Development, Evaluated In Phase 2 Study", GSK PRESS RELEASE, July 2009 (2009-07-01), XP 055544606, Retrieved from the Internet | UNDERWOOD ET AL.: "S/GSK1349572: A Next Generation Integrase Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical Isolates from Patients Experiencing Virologic Failure while on Raltegravir Therapy", IAS 2009 - 5TH CONFERENCE ON HIV PATHOGENESIS, TREATMENT AND PREVENTION, 19 July 2009 (2009-07-19), Cape Town South Africa, XP 055544612, Retrieved from the Internet | ROCKSTROH K.J. ET AL.: "Integrase inhibitors: Why do we need a new drug class for HIV therapy?", EUR J MED RES, vol. 14, no. III, November 2009 (2009-11-01), pages 1 - 3, XP021130215 DOI: http://dx.doi.org/10.1186/2047-783X-14-S3-1 | JOHNS ET AL.: "The Discovery of S/GSK1349572: A Once Daily Next-Generation Integrase Inhibitor with a Superior Resistance Profile", 17TH CROI, CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, 16 February 2010 (2010-02-16), San Francisco CA, XP 055539843 | POZNIAK ET AL.: "Efficacy and safety of TMC278 in antiretroviral-naive HIV- 1 patients: week 96 results of a phase Ilb randomized trial", AIDS, vol. 24, no. 1, 2 January 2010 (2010-01-02), pages 55 - 66, XP 055539845 DOI: http://dx.doi.org/10.1097/QAD.0b013e32833032ed |